has revolutionized the management of peptic ulcer disease, providing a permanent cure in most cases. Such treatment also represents first-line therapy for patients with low-grade gastric MALT lymphoma. 3 In view of rising resistance present study was undertaken to identify the most appropriate regimen for Helicobacter pylori eradication in Punjab.
METHODS
The study included 150 patients diagnosed to be Helicobacter pylori positive by rapid urease test, after obtaining informed consent, admitted between December-2013 to July-2016. The patients were then randomly divided into three groups each of 50, one received Sequential Therapy with Omeprazole (20 mg) plus Amoxicillin (1 g) twice/day for five days, followed by Omeprazole (20 mg) with Tinidazole (500 mg) twice/day and Clarithromycin (500 mg) twice/day for five consecutive days. Standard triple therapy group received Omeprazole (20 mg), Amoxicillin (1g) and Clarithromycin (500mg) twice/day for 14 days and third group received Quinolone-Based Triple Therapy Omeprazole (20mg bid), Amoxicillin (1gm bid), Levofloxacin (500mg bid) for 10 days. Patients were followed up no sooner than four weeks of completing therapy by rapid urease test to confirm eradication. In cases of duodenal or gastric ulcers compelling continued use of proton-pump inhibitors after completion of antibiotic therapy, patients were followed up four weeks after stopping proton-pump inhibitors.
Inclusion criteria
• Individuals of age more than 18 years age.
• Randomized after positive rapid urease test.
Exclusion criteria
• Chronic use of PPIs or H2-receptor antagonists. Eradication rates in three groups were then analyzed statistically using standard statistical methods mentioned with each parameter.
RESULTS
Endoscopic diagnosis in three groups was not significant with regards to presence of GERD, Gastric Ulcers, Duodenal Ulcers (p value>0.05) except for presence of erosive gastritis which was significantly higher in patients in quinolone group (p value<0.05) ( Table 1) .
Eradication rate was 90%, 86%, 82% in sequential therapy group, triple therapy group and fluroquinolone group respectively. However, there was no statistically significant difference in eradication rates in these groups (p value>0.05) ( Table 2) .
Comparison of follow-up rapid urease test in sequential vs standard triple therapy group. Eradication rate in sequential group was 90 percent whereas in standard triple therapy group was 86 percent. However, this difference was not statistically significant (p value >0.05) ( Table 3) .
Side effect profile in sequential vs standard triple therapy group. There was no significant difference in two groups in terms of side effects (Table 4 ).
Follow-up rapid urease test in sequential vs quinolone therapy group. With eradication rate in sequential group was 90 percent whereas in quinolone therapy group was 82 percent. However, this difference was not statistically significant (p value >0.05) ( Table 5 ).
Side effect profile in sequential vs Quinolone therapy group. There was no significant difference in two groups in terms of side effects (p value >0.05) (Table-6 ). Follow-up rapid urease test in standard triple therapy group vs quinolone therapy group. Eradication rate in standard therapy group was 86 percent whereas in quinolone therapy group was 82 percent. However, this difference was not statistically significant (p value >0.05) ( Table 7 ). There was no significant difference in two groups in terms of side effects (Table 8) .
DISCUSSION
Present study included 150 patients diagnosed to be Helicobacter pylori positive by rapid urease test, after obtaining informed consent. The patients were then randomly divided into three groups each of 50, one received Sequential Therapy, Standard Triple Therapy group and third group received Quinolone-Based Triple Therapy and patients were followed up atleast four weeks after completion of treatment.
Eradication rate for sequential therapy group was 90 percent. This finding was consistent with study conducted by Vaira et al, in Italy between 2003 and 2006 where eradication rate of 89 percent was obtained with sequential therapy. 4 Similar results were obtained in a study conducted by Zullo et al. 5 Eradication rate for 14 days standard triple therapy was 86 percent and this finding was consistent with results of study conducted by Yuan et al, where eradication rate of 84.4 percent was obtained with 14 days standard triple therapy. 6 Eradication rate for 10 days fluroquinolone based triple therapy was 82 percent. This finding was consistent with results of study conducted by Gisbert et al, where eradication rate of 83 percent was obtained with levofloxacin containing regimen. 7 Eradication rate was slightly higher in sequential therapy group (90 percent) compared to other two groups, however the results were statistically insignificant (p value>0.05) when all three groups were compared together suggesting all three regimens were equivalent in terms of achieving Helicobacter pylori eradication. No significant difference was found in terms of side effect profile in three groups These findings were consistent with a multi-center randomised control trial where in 10 days sequential therapy was compared with 14 days Triple Therapy conducted by Liou JM. 8 No difference was noted in eradication rates or adverse effects in two groups. Also, a meta-analysis and systematic review consisting of 46 randomised controlled trials concluded that eradication rates in 10 days sequential therapy and 14 days standard triple therapy were statistically insignificant. 9 Similarly results in this study were consistent with results of a study conducted by J. Molina-Infante where levofloxacin-based therapy was compared with sequential therapy. No difference was found with respect to eradication in two groups. 10 Results were consistent with a recent metaanalysis where seven trials were identified with 888 patients receiving first-line levofloxacin and 894 treated with standard therapy (Amoxicillin, Clarithromycin and proton pump inhibitor). This metanalysis concluded that Helicobacter pylori eradication rates with Levofloxacin-based first line therapy had equivalent results as that of standard first-line therapy. 11
CONCLUSION
Sequential therapy group had better eradication rates (90%) as compared to standard triple therapy group (86%) and fluroquinolone therapy group (82%) but results were not statistically significant when all three groups were compared together. Side effects profiles in all three groups were similar when compared together and there was insignificant difference in side effects of three groups. There was no significant difference in eradication rates or side effect profile when sequential therapy group was compared with triple therapy group. There was no significant difference in eradication rates or side effect profile when sequential therapy group was compared with fluroquinolone based triple therapy group. There was no significant difference in eradication rates or side effect profile when standard triple therapy group was compared with fluroquinolone based triple therapy group.
Resistance is an evolving process and hence antibiotic susceptibility and local treatment success rates must be monitored to update treatment selections. Though statistically insignificant, sequential therapy group had slight better eradication rates than triple therapy group further studies with large sample size are needed to recommend it as replacement for standard triple therapy. Standard triple therapy for 14 days can still be considered as first line regimen. In case of treatment failure antibiotic resistance should be evaluated before selecting next regimen for best outcomes. A large multicenter study, meta-analysis are required to recommend best eradication regimen for Indian population.
